Thus, different pheochromocytoma/paraganglioma tumour lesions may evolve different expression of somatostatin receptors, LAT1 and NET transporter proteins, which then potentially could manifest in variations in detectability using molecular imaging methods targeting these specific properties. The gene discussed is LAT; the disease is neoplasm.